Share This Article:

Induction of Apoptosis in Lung Cancer Cells by TRAIL and L-leucyl-L-leucine Methyl Ester

Abstract Full-Text HTML XML Download Download as PDF (Size:1788KB) PP. 418-430
DOI: 10.4236/jct.2011.23057    4,773 Downloads   9,009 Views   Citations

ABSTRACT

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a member of the tumor necrosis factor superfamily that induces apoptosis in many tumor cells. Previous studies suggested that TRAIL treatment might also cause release of lysosomal cathepsin proteases to the cytosol, thus further promoting apoptosis. L-leucyl-L-leucine methyl ester (LeuLeuOMe) is a lysosome-destabilizing agent that may cause release of cathepsins into the cytosol and ensuing apoptosis. We hypothesized that a combination of TRAIL and LeuLeuOMe may synergistically promote apoptosis in lung cancer cells. The human epidermoid lung carcinoma cell line Calu-1 (TRAIL-resistant) and human large cell lung carcinoma cell line NCI-H460 (TRAIL-sensitive) were assayed for sensitivity to TRAIL and LeuLeuOMe, given alone or in different combination doses. Each agent alone induced a dose-dependent cytotoxicity, with substantially different efficacies of the two agents for the two cell types. When both agents were combined, synergistic cytotoxicity was achieved even in the TRAIL-resistant cells. TRAIL-induced cytotoxicity was completely inhibited by pan-caspase inhibitor z-VAD-fmk, but not by cysteine protease inhibitor E-64d. Conversely, E-64d totally blocked LeuLeuOMe-induced cytotoxicity. TRAIL caused mitochondrial damage, while enlarged lysosomes and lysosomal rupture were observed in LeuLeuOMe-treated cells. Our data suggest that, while TRAIL and LeuLeuOMe cause apoptosis through pathways that differ in their involvement of lysosomal cysteine proteases, mitochondrial and lysosomal desta-bilization have converging pro-apoptotic effects. Thus, the synergy of TRAIL and LeuLeuOMe may be used therapeutically to promote apoptosis in lung cancers, even those with intrinsic or acquired resistance to TRAIL.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

X. Sun, L. Bandura-Morgan and W. Zacharias, "Induction of Apoptosis in Lung Cancer Cells by TRAIL and L-leucyl-L-leucine Methyl Ester," Journal of Cancer Therapy, Vol. 2 No. 3, 2011, pp. 418-430. doi: 10.4236/jct.2011.23057.

References

[1] S. Ramalingam and C. P. Belani, “Recent Advances in Targeted Therapy for Non-Small Cell Lung Cancer,” Expert Opinion in Therapeutic Targets, Vol. 11, No. 2, 2007, pp. 245-257. doi:10.1517/14728222.11.2.245
[2] N. W. Choong, R. Salgia and E. E. Vokes, “Key Signaling Pathways and Targets in Lung Cancer Therapy,” Clinical Lung Cancer, Vol. 8, No. 2, 2007, pp. S52-S60. doi:10.3816/CLC.2007.s.002
[3] L. R. Motadi, N. L. Misso, Z. Dlamini and K. D. Bhoola, “Molecular Genetics and Mechanisms of Apoptosis in Carcinomas of the Lung and Pleura: Therapeutic Targets,” International Immunopharmacology, Vol. 7, No. 14, 2007, pp. 1934-1947. doi:10.1016/j.intimp.2007.07.013
[4] M. Takahashi, O. Inanami, N. Kubota, M. Tsujitani, H. Yasui, A. Ogura, et al., “Enhancement of Cell Death by TNF Alpha-Related Apoptosis-Inducing Ligand (TRAIL) in Human Lung Carcinoma A549 Cells Exposed to X Rays under Hypoxia,” Journal of Radiation Research, Vol. 48, No. 6, 2007, pp. 461-468. doi:10.1269/jrr.07028
[5] H. Zhuang, W. Jiang, W. Cheng, K. Qian, W. Dong, L. Cao, et al., “Down-Regulation of HSP27 Sensitizes TRAIL-Resistant Tumor Cell to TRAIL-Induced Apoptosis,” Lung Cancer, Vol. 68, No. 1, 2010, pp. 27-38. doi:10.1016/j.lungcan.2009.05.014
[6] G. Mellier, S. Huang, K. Shenoy and S. Pervaiz, “TRAILing Death in Cancer,” Molecular Aspects of Medicine, Vol. 31, No. 1, 2010, pp. 93-112. doi:10.1016/j.mam.2009.12.002
[7] B. Pennarun, A. Meijer, E. G. de Vries, J. H. Kleibeuker, F. Kruyt and S. de Jong, “Playing the DISC: Turning on TRAIL Death Receptor-Mediated Apoptosis in Cancer,” Biochimica Biophysica Acta, Vol. 1805, No. 2, 2010, pp. 123-140.
[8] J. Voortman, T. P. Resende, E. Abou, M. A. Hassan, G. Giaccone and F. A. Kruyt, “TRAIL Therapy in Non-Small Cell Lung Cancer Cells: Sensitization to Death Receptor-Mediated Apoptosis by Proteasome Inhibitor Bortezomib,” Molecular Cancer Therapeutics, Vol. 6, No. 7, 2007, pp. 2103-2112. doi:10.1158/1535-7163.MCT-07-0167
[9] J. Y. Lee, S. Huerta-Yepez, M. Vega, S. Baritaki, D. A. Spandidos and B. Bonavida, “The NO TRAIL to YES TRAIL in Cancer Therapy,” International Journal of Oncology, Vol. 31, No. 4, 2007, pp. 685-691.
[10] A. Ashkenazi, R. C. Pai, S. Fong, et al., “Safety and Antitumor Activity of Recombinant Soluble Apo2 Ligand,” Journal of Clinical Investigation, Vol. 104, No. 2, 1999, pp. 155-162. doi:10.1172/JCI6926
[11] H. Walczak, R. E. Miller, K. Ariail, B. Gliniak, T. S. Griffith, M. Kubin, et al., “Tumoricidal Activity of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in Vivo,” Nature Medicine, Vol. 5, No. 2, 1999. pp. 157-163. doi:10.1038/5517
[12] E. Cretney, K. Takeda, H. Yagita, M. Glaccum, J. J. Peschon and M. J. Smyth, “Increased Susceptibility to Tumor Initiation and Metastasis in TNF-Related Apoptosis-Inducing Ligand-Deficient Mice,” Journal of Immunology, Vol. 168, No. 3, 2002, pp. 1356-1361.
[13] F. Dong, L. Wang, J. J. Davis, W. Hu, L. Zhang, W. Guo, et al., “Eliminating Established Tumor in nu/nu Nude Mice by a Tumor Necrosis Factor-Alpha-Related Apoptosis-Inducing Ligand-Armed Oncolytic Adenovirus,” Clinical Cancer Research, Vol. 12, No. 17, 2006, pp. 5224-5230. doi:10.1158/1078-0432.CCR-06-0244
[14] N. S. Nagaraj, N. Vigneswaran and W. Zacharias, “Hypoxia Inhibits TRAIL-Induced Tumor Cell Apoptosis: Involvement of Lysosomal Cathepsins,” Apoptosis, Vol. 12, No. 1, 2007, pp. 125-139. doi:10.1007/s10495-006-0490-1
[15] P. A. Mayes, L. Campbell, M. S. Ricci, J. P. Plastaras, D. T. Dicker and W. S. El-Deiry, “Modulation of TRAIL- Induced Tumor Cell Apoptosis in a Hypoxic Environment,” Cancer Biology & Therapy, Vol. 4, No. 10, 2005, pp. 1068-1074. doi:10.4161/cbt.4.10.2255
[16] D. A. Nelson, T. T. Tan, A. B. Rabson, D. Anderson, K. Degenhardt and E. White, “Hypoxia and Defective Apoptosis Drive Genomic Instability and Tumorigenesis,” Genes & Development, Vol. 18, No. 17, 2004, pp. 2095-2107. doi:10.1101/gad.1204904
[17] N. S. Nagaraj, N. Vigneswaran and W. Zacharias, “Cathepsin B Mediates TRAIL-Induced Apoptosis in Oral Cancer Cells,” Journal of Cancer Research & Clinical Oncology, Vol. 132, No. 3, 2006, pp. 171-183. doi:10.1007/s00432-005-0053-9
[18] N. Vigneswaran, J. Wu, N. Nagaraj, K. Adler-Storthz and W. Zacharias, “Differential Susceptibility of Metastatic and Primary Oral Cancer Cells to TRAIL-Induced Apoptosis,” International Journal of Oncology, Vol. 26, No. 1, 2005, pp. 103-112.
[19] N. Vigneswaran, D. C. Baucum, J. Wu, Y. Lou, J. Bouquot, S. Muller and W. Zacharias, “Repression of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) but Not Its Receptors during Oral Cancer Progression,” BMC Cancer, Vol. 7, 2007, p. 108. doi:10.1186/1471-2407-7-108
[20] N. W. Werneburg, M. E. Guicciardi, S. F. Bronk, S. H. Kaufmann and G. J. Gores, “Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Activates a Lysosomal Pathway of Apoptosis That is Regulated by Bcl-2 Proteins,” Journal of Biological Chemistry, Vol. 282, No. 39, 2007, pp. 28960-28970. doi:10.1074/jbc.M705671200
[21] N. S. Nagaraj, N. Vigneswaran and W. Zacharias, “Hypoxia-Mediated Apoptosis in Oral Carcinoma Cells Occurs via Two Independent Pathways,” Molecular Cancer, Vol. 3, 2004, p. 38. doi:10.1186/1476-4598-3-38
[22] T. Kurz, A. Terman, B. Gustafsson and U. T. Brunk, “Lysosomes in Iron Metabolism, Ageing and Apoptosis,” Histochemistry and Cell Biology, Vol. 129, No. 2, 2008, pp. 389-406. doi:10.1007/s00418-008-0394-y
[23] P. Boya and G. Kroemer, “Lysosomal Membrane Permeabilization in Cell Death,” Oncogene, Vol. 27, No. 50, 2008, pp. 6434-6451. doi:10.1038/onc.2008.310
[24] T. Kirkegaard and M. J??ttel?, “Lysosomal Involvement in Cell Death and Cancer,” Biochimica Biophysica Acta, Vol. 1793, No. 4, 2009, pp. 746-754. doi:10.1016/j.bbamcr.2008.09.008
[25] A. Puissant, M. Dufies, S. Raynaud, J. P. Cassuto and P. Auberger, “Targeting Lysosomes to Eradicate Imatinib-Resistant Chronic Myelogenous Leukemia Cells,” Leukemia, Vol. 24, No. 5, 2010, pp. 1099-1101. doi:10.1038/leu.2010.55
[26] U. Repnik and B. Turk, “Lysosomal–Mitochondrial Cross-Talk during Cell Death,” Mitochondrion, Vol. 10, No. 6, 2010, pp. 662-669. doi:10.1016/j.mito.2010.07.008
[27] B. Joy, R. Sivadasan, T. E. Abraham, M. John, P. K. Sobhan and M. T. R. S. Seervi, “Lysosomal Destabilization and Cathepsin B Contributes for Cytochrome C Release and Caspase Activation in Embelin-Induced Apoptosis,” Molecular Carcinogenesis, Vol. 49, No. 4, 2010, pp. 324-336.
[28] W. Ding, T. Cai, H. Zhu, R. Wu, C. Tu, L. Yang et al. “Synergistic Antitumor Effect of TRAIL in Combination with Sunitinib in Vitro and in Vivo,” Cancer Letters, Vol. 293, No. 2, 2010, pp. 158-166. doi:10.1016/j.canlet.2010.01.005
[29] H. Zhu, W. J. Ding, R. Wu, Q. J. Weng, J. S. Lou, R. J. Jin, et al., “Synergistic Anti-Cancer Activity by the Combination of TRAIL/APO-2L and Celastrol,” Cancer Investigations, Vol. 28, No. 1, 2010, pp. 23-32. . doi:10.3109/07357900903095664
[30] A.-C. Johansson, H. Appelqvist, C. Nilsson, K. Kagedal, K. Roberg and K. Oellinger, “Regulation of Apoptosis- Associated Lysosomal Membrane Permeabilization,” Apoptosis, Vol. 15, No. 5, 2010, pp. 527-540. doi:10.1007/s10495-009-0452-5
[31] Y. P. Keepers, P. E., Pizao, G. J. Peters, J. van Ark-Otte, B. Winograd and H. M. Pinedo, “Comparison of the Sulforhodamine B Protein and Tetrazolium (MTT) Assays for in Vitro Chemosensitivity Testing,” European Journal of Cancer, Vol. 27, No. 7, 1991, pp. 897-900. doi:10.1016/0277-5379(91)90142-Z
[32] S.-Y. Sun, P. Yue, J.-Y. Zhou, Y. Wang, H.-R. C. Kim, R. Lotan, et al., “Overexpression of BCL2 Blocks TNF-Related Apoptosis-Inducing Ligand (TRAIL)-Induced Apoptosis in Human Lung Cancer Cells,” Biochemical and Biophysical Research Communications, Vol. 280, No. 3, 2001, pp. 788-797. doi:10.1006/bbrc.2000.4218
[33] M. C. Berenbaum, “Synergy, Additivism and Antagonism in Immunosuppression,” Clinical & Experimental Immunology, Vol. 28, No. 1, 1977, pp. 1-18.
[34] H. Erdal, M. Berndtsson, J. Castro, U. Brunk, M. C. Shoshan and S. Linder, “Induction of Lysosomal Membrane Permeabilization by Compounds that Activate P53-Independent Apoptosis,” Proceedings of the National Academy of Sciences USA, Vol. 102, No. 1, 2005, pp. 192-197. doi:10.1073/pnas.0408592102
[35] J. R. Piccotti, M. S. LaGattuta, S. A. Knight, A. J. Gonzales and M. R. Bleavins, “Induction of Apoptosis by Cationic Amphiphilic Drugs Amiodarone and Imipramine,” Drug & Chemical Toxicology, Vol. 28, No. 1, 2005, pp. 117-133.
[36] L. Groth-Pedersen, M. S. Ostenfeld, M. Hoyer-Hansen, J. Nylandsted and M. Jaattela, “Vincristine Induces Dramatic Lysosomal Changes and Sensitizes Cancer Cells to Lysosome-Destabilizing Siramesine,” Cancer Research, Vol. 67, No. 5, 2007, pp. 2217-2225. doi:10.1158/0008-5472.CAN-06-3520

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.